| HOME >> BIOLOGY >> TECHNOLOGY |
TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a leading vertically-integrated pharmaceutical company with major operations in China and the U.S., today announced its newly appointed Chairman and CEO Mr. Douglas MacLellan will present at Rodman & Renshaw's Annual Global Investment Conference taking place on Wednesday, November 12th, 2008 at the New York Palace Hotel in New York City.
Mr. MacLellan will provide an informative overview of AMDL's core business and growth strategy for its China specialty pharmaceuticals, in-vitro diagnostics and cancer therapeutic divisions. The Company has an aggressive and focused approach to capitalize on these three market sectors, positioning AMDL as one of most rapidly growing and highly-opportunistic micro-cap investment prospects in the vertically-integrated, specialty pharmaceutical sector.
In 2008 alone, AMDL met numerous operational milestones which include: securing more than $25 million in sales contracts for its best-selling HPE anti-aging product line; expanding AMDL's overall revenue opportunity for HPE by launching additional HPE product formulations; and successfully securing US FDA clearance for AMDL's ELISA DR-70(R) FDP cancer diagnostic test. The ELISA DR-70(R) FDP cancer diagnostic test is the first test to be cleared by the US FDA in over 25 years for the monitoring of colorectal cancer.
Attendees wishing to learn more about the Company can attend Mr.
MacLellan's presentation which is scheduled at 9:55 a.m. EST in the Henry
Salon, 5th Floor of the New York Palace Hotel. Additionally, interested
investors can visit the Company's corporate website at
| SOURCE AMDL, Inc. Copyright©2008 PR Newswire. All rights reserved |